Shan Ahmed Khan

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

10x Genomics (TXG) Stock: Citi Downgrade, AI Partnerships and 2026 Forecast After December 11 Sell-Off

10x Genomics (TXG) Stock: Citi Downgrade, AI Partnerships and 2026 Forecast After December 11 Sell-Off

10x Genomics, Inc. — a leading player in single-cell and spatial biology — is back in the spotlight after a sharp share-price drop on 11 December 2025. A high-profile analyst downgrade from Citigroup hit the stock the same morning, even as the company pushes forward with ambitious AI collaborations and cancer atlas projects that could shape its long-term growth story. MarketScreener+2StockStory+2
11 December 2025
····
Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals Limited is ending 2025 in a paradoxical position: commercially successful, rich in late‑stage oncology assets, but trading near its 12‑month lows amid SEC scrutiny, an FDA setback and a growing stack of class‑action lawsuits. At the same time, new clinical milestones and a fresh collaboration with Varian are reinforcing the long‑term radiopharmaceutical growth story.
11 December 2025
···
Affirm Holdings (AFRM) Stock on December 11, 2025: Shopify Expansion, Institutional Buying and Lofty Price Targets Put BNPL Leader Back in Focus

Affirm Holdings (AFRM) Stock on December 11, 2025: Shopify Expansion, Institutional Buying and Lofty Price Targets Put BNPL Leader Back in Focus

As of December 11, 2025, Affirm Holdings, Inc. is once again one of the most closely watched names in fintech. The buy now, pay later pioneer has turned the corner into profitability, deepened its global partnership with Shopify, attracted fresh institutional money—and still trades at one of the richest valuations in the sector.
11 December 2025
··
Comstock Resources (CRK) Stock: December 11, 2025 News, Price Drop, Forecasts and AI-Powered Gas Demand Outlook

Comstock Resources (CRK) Stock: December 11, 2025 News, Price Drop, Forecasts and AI-Powered Gas Demand Outlook

As of the afternoon of December 11, 2025, Comstock Resources, Inc. is trading around $21.6 per share, down roughly 6% on the day and about 9.8% over the past week, though the stock remains just over 40% higher than it was a year ago.TradingView+1 Within its 52‑week range of roughly $14.65 to $31.17, CRK now sits about 30% below its high but nearly 48% above its low, underlining how sharp this week’s reversal has been.Investing.com
11 December 2025
··
New Gold Inc (NGD) Stock: 201% Rally, $7 Billion Coeur Mining Buyout and December 2025 Analyst Outlook

New Gold Inc (NGD) Stock: 201% Rally, $7 Billion Coeur Mining Buyout and December 2025 Analyst Outlook

As of December 11, 2025, New Gold Inc has turned into one of the most closely watched gold miners on the market. The Canadian producer has enjoyed a 201% share‑price surge over the past year, posted record free cash flow, agreed to a $7 billion all‑stock acquisition by Coeur Mining, and now sits under an unusually bullish wall of analyst “Buy” ratings. Finimize+2Q4 CDN+2
11 December 2025
·····
Polestar Automotive (PSNY) Stock Plunges After Reverse Split – Latest News, Analyst Forecasts and 2025–2026 Outlook

Polestar Automotive (PSNY) Stock Plunges After Reverse Split – Latest News, Analyst Forecasts and 2025–2026 Outlook

Polestar Automotive Holding UK PLC, the Swedish premium electric-vehicle maker backed by China’s Geely, is having one of its most volatile weeks since listing. After a 1‑for‑30 reverse stock split and a fresh Nasdaq warning, the newly consolidated Polestar stock has swung wildly, crashing to fresh 52‑week lows even as the company reports almost 50% revenue growth for 2025 so far. Ad-Hoc News+1
11 December 2025
·
Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

NEW YORK – December 11, 2025 – Shares of Immunovant, Inc. were sharply in focus on Thursday after the clinical‑stage immunology company announced a $550 million common stock financing designed to fund development and a potential commercial launch of its lead FcRn inhibitor, IMVT‑1402, in Graves’ disease.Immunovant, Inc.+1
11 December 2025
····
Coeur Mining (CDE) Stock on December 11, 2025: Palmarejo Breakthroughs, $7B New Gold Deal and What Comes Next

Coeur Mining (CDE) Stock on December 11, 2025: Palmarejo Breakthroughs, $7B New Gold Deal and What Comes Next

Coeur Mining, Inc. has turned into one of 2025’s most dramatic comeback stories in precious metals. The U.S.-based gold‑and‑silver producer has delivered record cash flow, launched its largest exploration push in more than a decade, and unveiled a $7 billion all‑stock acquisition of New Gold Inc. that would create a new North American mining heavyweight. Coeur Mining+2Proactiveinvestors NA+2
11 December 2025
···
Belite Bio (NASDAQ: BLTE) Stock: DRAGON Trial Breakthrough, $350 Million Offering and Outlook After a 130% Rally

Belite Bio (NASDAQ: BLTE) Stock: DRAGON Trial Breakthrough, $350 Million Offering and Outlook After a 130% Rally

Belite Bio, Inc. has turned into one of 2025’s most closely watched biotech stories. On the back of a pivotal Phase 3 win in Stargardt disease and a large equity raise, the small-cap ophthalmology specialist has seen its share price more than double this year and its market value climb into the multi‑billion‑dollar range.BioPharma Dive+1
11 December 2025
·
1 … 503 504 505 506 507 … 608
Follow on Google News
Add as preferred source Open in Google News
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 BUY IN STAGES

Xylem

NYSE: XYL 93 / 100
#2 BUY THE PULLBACK

Hubbell

NYSE: HUBB 91 / 100
#3 BUY ON WEAKNESS

Visa

NYSE: V 89 / 100
#4 SELECTIVE BUY

Bunge

NYSE: BG 86 / 100
#5 SPECULATIVE BUY

Vertiv

NYSE: VRT 82 / 100
View full portfolio
Editorial model selection. Not personalised advice.